Health Catalyst (HCAT) Set to Announce Quarterly Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is set to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $74.72 million for the quarter, compared to analysts’ expectations of $74.81 million. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $7.63 on Wednesday. The company’s fifty day moving average is $6.63 and its 200-day moving average is $7.48. Health Catalyst has a twelve month low of $5.45 and a twelve month high of $14.37.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of Health Catalyst stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the sale, the chief operating officer now directly owns 155,215 shares in the company, valued at approximately $954,572.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 8,564 shares of company stock worth $54,889. Insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on HCAT shares. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th. Wells Fargo & Company reduced their price target on shares of Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, May 10th. Piper Sandler reduced their price target on shares of Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a research report on Thursday, June 6th. Evercore ISI dropped their price objective on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of Health Catalyst in a report on Tuesday, May 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.91.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.